Unilife Medical Solutions to market its products at pharmaceutical industry event

Unilife Medical Solutions Limited ("Unilife" or "the Company") (ASX: UNI) (PINKSHEETS: UNIFF) today announced it will be exhibiting at two upcoming pharmaceutical trade shows and conferences.

The Parenteral Drug Association (PDA) Universe of Pre-filled Syringes and Injection Devices, Conference and Exhibition takes place between October 27 and 30, 2009 in Venice, Italy. It is the pre-eminent annual gathering of pharmaceutical companies and device manufacturers on matters relating to prefillable injection systems for parenteral drug formulations. Unilife can be found at Booth E.

PharmaPack 2010 takes place February 1 and 2, 2010 in Paris, France. More than 200 companies will be exhibiting at PharmaPack, with over 2,200 people expected to attend including major decision-makers from pharmaceutical, biopharmaceutical and healthcare companies. Unilife will be exhibiting at Booth A34.

Unilife's proprietary portfolio of ready-to-fill glass and clinical safety syringes feature a unique automatic (passive) retraction mechanism which allows operators to control the speed of needle withdrawal directly from the body into the barrel of the syringe to help protect those at risk of needlestick injuries and other unsafe injection practices.

Unilife CEO Alan Shortall said the PDA Universe of Prefilled Syringes Conference to occur in Venice later this month would mark the first time that the Company and its products would be marketed at a landmark pharmaceutical industry event.

"We are especially proud of our representation at PDA Venice, as the event symbolises the launch of our Company onto the pharmaceutical stage for parenteral drug delivery devices. We anticipate a good reception for our range of safety syringes, with meetings being scheduled with a number of pharmaceutical companies and other interested parties."


Unilife Medical Solution


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Three-year MRC funded project to develop new drugs for treating childhood epilepsy